AVALO THERAPEUTICS, INC. (AVTX) Gross profit 2016–2023
AVALO THERAPEUTICS, INC. (AVTX) annual gross profit history from SEC filings — each fiscal year as reported.
$640,000FY2023 · since FY2016: $1.2M → $640,000
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | $640,000 | -95.6% |
| FY2022 | $14.6M | +274.1% |
| FY2021 | $3.9M | -38.9% |
| FY2020 | $6.4M | -12.5% |
| FY2019 | $7.3M | +94.2% |
| FY2018 | $3.8M | -86.1% |
| FY2017 | $27.2M | +2257.1% |
| FY2016 | $1.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More AVTX financial trends
AVTX RevenueAVTX Net incomeAVTX Net marginAVTX Gross marginAVTX Operating incomeAVTX Operating marginAVTX Operating cash flowAVTX Free cash flowAVTX Capital expendituresAVTX Return on equityAVTX Stock buybacksAVTX Dividends paidAVTX Total assetsAVTX Total liabilitiesAVTX Shareholders’ equityAVTX overview →